Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. The Bridgewater, N.J.-based pharmaceutical company also said Wednesday that it was acquiring INS1148, ...

Why some people experience long-lasting physical and mental effects from covid-19 could be linked to chronic inflammation, according to new research that experts say could help develop new treatments ...

Five years after the start of the pandemic, a group of researchers from Beth Israel Deaconess Medical Center is one step closer to identifying the cause of the mysterious and debilitating chronic ...

Children with a rare form of cancer called neuroblastoma which hasn’t responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to ...

If you’re older than 12 and test positive for COVID-19, you most likely qualify to receive monoclonal antibody treatment on Texas’ dime. For most, the largest barrier to getting the early-stage ...

Primary immune thrombocytopenia (ITP) is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting, which can lead to life-threatening ...

Sickle cell disease, sleep disorders and lung cancer: these are just a few of the medical issues that were under investigation in at least 383 clinical trials that have had research grants terminated ...

GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid. Part of a class of drugs known ...

Nearly a third of Americans say someone they know died while being treated for COVID-19, and many think hospital treatment protocols may have been a factor in those deaths. The latest Rasmussen ...